Hypoxia Unlocks a New Target in Childhood Liver Cancer
A new study in hepatoblastoma, the most common malignant liver tumor in children, identifies trefoil factor 3 (TFF3) as a key hypoxia-inducible factor driving tumor progression and drug resistance. Researchers found that low-oxygen conditions, a hallmark of aggressive tumors, trigger broad transcriptional reprogramming and significantly upregulate TFF3. This secreted oncogenic peptide promotes cancer cell proliferation, anchorage-independent growth, and resistance to cisplatin chemotherapy. In a mouse model, silencing TFF3 suppressed tumor formation and angiogenesis. Mechanistically, TFF3 sustains C-MYC expression and modulates the mTOR/GSK3β signaling pathway, positioning it as a central node in the tumorigenic network activated by the hypoxic tumor microenvironment.
Study Significance: This research directly addresses the critical need for new therapeutic targets in advanced and relapsed hepatoblastoma, where outcomes remain poor. For oncologists and cancer biologists, TFF3 emerges as a promising dual-purpose target: a potential biomarker detectable in plasma for liquid biopsy applications and a novel point for therapeutic intervention to disrupt hypoxia-driven oncogenic signaling, C-MYC stability, and chemoresistance. Its role in modulating key pathways like mTOR underscores its potential within the growing field of precision oncology for pediatric solid tumors.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
